By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Dynamic Business Location.

Apeiron tests effectiveness of APN01 on COVID-19 patients

COVID-19-Research © Medical University of Vienna

The Viennese company Apeiron Biologics AG is making use of a capital increase to further develop its COVID-19 and cell therapy pipeline. More specifically, it is examining the effectiveness of its drug candidate APN01 on patients who are seriously ill with COVID-19. This drug is designed to block the virus and protect the patients from respiratory failure. According to Apeiron, the financing is for future clinical studies as well as the availability of materials for treating COVID-19 patients. 200 ventilated patients are being treated with APNO1 within the context of phase II clinical studies which are already being conducted. The primary objective of the study is to investigate the clinical effectiveness of APN01 as well as the safety and tolerability of PNO1 in this patient population. The company believes an accelerated approval of the drug is conceivable if these goals are met.

APN01 is a recombinant form of ACE2 which blocks the binding of the virus on the basis of competitive binding on the viral spike protein and also has an anti-inflammatory effect. The product candidate was developed by the company founded by Josef Penninger especially for the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).

Read more here about COVID-19 research in Austria.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin



Meet us at events, seminars and trade shows - worldwide.

  • Smart Manufacturing and Artificial Intelligence in Austria

    5.08.2021/15.00 CST (China Standard Time), Virtual Event

  • Meet us @ Belt and Road Summit Hong Kong 2021

    01.09-02.09 2021, Virtual Event

Austria Map

Find the perfect location for your company

A country like Austria considered to be an especially good terrain for upscale industrial segments, and with a particular emphasis on research and environmental friendliness, represents a major opportunity for SIAD. Our corporate goal is namely to assist the customer and provide support in improving the productivity and the environmental compatibility of its work processes.


More testimonials

news from the business location Austria

Online real estate specialist Propster obtains fresh capital

A digital “all-round programme” for implementing real estate projects is offered by the Viennese startup Propster established in 2017.

4 Reasons for Evaluating Austria as the First Step for Internationalisation of Your Startup

Just recently the latest edition of the Austrian Start Up Monitor was published. The report, once again, shows that Austria has a very dynamic founder scene. Just think of Prescreen, mySugar, Bitpanda or Bitmovin; Austria has spawned numerous, internationally well-known flagships within the startup community.

More news All blog posts